In the latest market close, Biogen Inc. (BIIB) reached $219.40, with a +0.04% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.63%. Meanwhile, the Dow gained 0.2%, and the Nasdaq, a tech-heavy index, added 0.82%.The company's shares have seen an increase of 0.1% over the last month, not keeping up with the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76%.Investors will be eagerly watching for the performance of Biogen Inc. in its upcoming ...

It has been about a month since the last earnings report for Biogen Inc. (BIIB) . Shares have added about 2.6% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Biogen Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q4 Earnings & Sales Miss EstimatesBiogen’s fo ...

In the latest market close, Biogen Inc. (BIIB) reached $227.36, with a -1.18% movement compared to the previous day. This move lagged the S&P 500's daily gain of 1.12%. Meanwhile, the Dow experienced a rise of 0.61%, and the technology-dominated Nasdaq saw an increase of 1.54%.The company's stock has dropped by 5.99% in the past month, falling short of the Medical sector's gain of 2.49% and the S&P 500's gain of 2.06%.Investors will be eagerly watching for the performance of Biogen Inc. in its upcoming earn ...

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most participants treated with SPINRAZA after gene therapy CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label R ...

New data advances understanding of new approaches to treating Alzheimer's diseaseResearch on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced it will present new data from its Alzheimer's disease (AD) portfolio at the upcoming International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place March 5-9 in Lisbon, Portugal and virtually. The presentations include new data for its ora ...

If you’re looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ:IBB) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry.  But that exchange traded fund (ETF) hasn’t done well in recent years. In the past three years, its total return was 0.95% in 2021, -13.69% in 2022 and 3.76% in 2023. Year-to-date (YTD), it’s up 2.91%, considerably less than the 8.74% for the SPDR S&P 500 ETF Trust (NYSEARCA:SP ...

Biogen Inc. (NASDAQ:BIIB) TD Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Michael McDonnell - Chief Financial Officer Alisha Alaimo - President, Head of North America Priya Singhal - Head of Development and Interim Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen Michael McDonnell [Call Starts Abruptly] So good morning and thank you very much to everyone for being with us today. I would say that the launch of LEQEMBI is going in line ...

Biogen Inc. (NASDAQ:BIIB) TD Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Michael McDonnell - Chief Financial Officer Alisha Alaimo - President, Head of North America Priya Singhal - Head of Development and Interim Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen Michael McDonnell [Call Starts Abruptly] So good morning and thank you very much to everyone for being with us today. I would say that the launch of LEQEMBI is going in line ...

On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (BIIB 1.82%) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311. One driver for that anticipated growth is the company's newly launched drug called Leqembi, which aims to treat Alzheimer's disease. But Leqembi is just one of four recent launches, with the other medicines treating conditions like postpartum depression and amyotrophic lateral sclerosis (ALS).Schmidt is likely to ...

Company Performance - Biogen Inc. (BIIB) ended the latest trading session at $221.74, reflecting a -0.98% change from the previous close, which is less than the S&P 500's daily loss of 0.17% [1] - Over the past month, Biogen's shares have decreased by 9.37%, while the Medical sector gained 5.93% and the S&P 500 gained 3.98% [1] - The upcoming earnings report is expected to show an EPS of $3.47, a 2.06% increase from the prior-year quarter, with revenue estimated at $2.32 billion, indicating a 5.67% decrease year-over-year [1] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict earnings of $15.48 per share and revenue of $9.45 billion, reflecting changes of +5.16% and -3.91% from the previous year, respectively [2] - Recent modifications to analyst estimates for Biogen indicate evolving short-term business trends, with positive revisions suggesting a favorable outlook on the company's health and profitability [2] Valuation Metrics - Biogen currently has a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 1.51% in the past month [3] - The company is trading at a Forward P/E ratio of 14.46, which is a discount compared to the industry's average Forward P/E of 22.45 [3] - Biogen's PEG ratio stands at 1.87, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.51 [3] Industry Overview - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 85 [4] - The strength of individual industry groups is measured by the Zacks Industry Rank, which is based on the average Zacks Rank of individual stocks within these groups [4]